126 related articles for article (PubMed ID: 12358876)
1. Platelet contractile force (PCF) and clot elastic modulus (CEM) are elevated in diabetic patients with chest pain.
Carr ME; Krishnaswami A; Martin EJ
Diabet Med; 2002 Oct; 19(10):862-6. PubMed ID: 12358876
[TBL] [Abstract][Full Text] [Related]
2. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus.
Krishnaswami A; Carr ME; Jesse RL; Kontos MC; Minisi AJ; Ornato JP; Vetrovec GW; Martin EJ
Thromb Haemost; 2002 Nov; 88(5):739-44. PubMed ID: 12428087
[TBL] [Abstract][Full Text] [Related]
3. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation.
Carr ME; Martin EJ; Carr SL
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):193-7. PubMed ID: 11943932
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
Carr ME; Martin EJ; Kuhn JG; Seremetis SV
Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
[TBL] [Abstract][Full Text] [Related]
5. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
[TBL] [Abstract][Full Text] [Related]
6. Development of platelet contractile force as a research and clinical measure of platelet function.
Carr ME
Cell Biochem Biophys; 2003; 38(1):55-78. PubMed ID: 12663942
[TBL] [Abstract][Full Text] [Related]
7. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
[TBL] [Abstract][Full Text] [Related]
8. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
[TBL] [Abstract][Full Text] [Related]
9. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
[TBL] [Abstract][Full Text] [Related]
10. Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans--two case reports.
Carr ME; Hackney MH; Hines SJ; Heddinger SP; Carr SL; Martin EJ
Vasc Endovascular Surg; 2002; 36(6):473-80. PubMed ID: 12476239
[TBL] [Abstract][Full Text] [Related]
11. Examining platelet-fibrin interactions during traumatic shock in a swine model using platelet contractile force and clot elastic modulus.
White NJ; Martin EJ; Brophy DF; Ward KR
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):379-87. PubMed ID: 21537163
[TBL] [Abstract][Full Text] [Related]
12. A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease.
Brophy DF; Martin RJ; Gehr TW; Carr ME
Thromb J; 2005 Mar; 3(1):3. PubMed ID: 15796773
[TBL] [Abstract][Full Text] [Related]
13. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Carr ME; Carr SL; Tildon T; Fisher LM; Martin EJ
J Thromb Haemost; 2003 Feb; 1(2):243-9. PubMed ID: 12871496
[TBL] [Abstract][Full Text] [Related]
14. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
Brophy DF; Martin EJ; Christian Barrett J; Nolte ME; Kuhn JG; Gerk PM; Carr ME; Pelzer H; Agersø H; Ezban M; Hedner U
Haemophilia; 2011 Sep; 17(5):e949-57. PubMed ID: 21362113
[TBL] [Abstract][Full Text] [Related]
15. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma.
Carr ME; Zekert SL
Am J Physiol; 1994 Mar; 266(3 Pt 2):H1195-201. PubMed ID: 8160823
[TBL] [Abstract][Full Text] [Related]
16. [Multivariate analysis for the understanding of typical diabetic hemostasis criteria. 2. Prevalent thrombocytic markers].
Syrbe G; Schröder H; Keil E; Jütte A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(5):725-9. PubMed ID: 1709906
[TBL] [Abstract][Full Text] [Related]
17. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development.
Carr ME; Carr SL
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):79-86. PubMed ID: 7795157
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modulus.
Carr ME; Carr SL; Hantgan RR; Braaten J
Thromb Haemost; 1995 Mar; 73(3):499-505. PubMed ID: 7667835
[TBL] [Abstract][Full Text] [Related]
19. Coagulopathy during cardiac arrest and resuscitation in a swine model of electrically induced ventricular fibrillation.
White NJ; Leong BS; Brueckner J; Martin EJ; Brophy DF; Peberdy MA; Ornato J; Ward KR
Resuscitation; 2011 Jul; 82(7):925-31. PubMed ID: 21482008
[TBL] [Abstract][Full Text] [Related]
20. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control.
Watala C; Golanski J; Pluta J; Boncler M; Rozalski M; Luzak B; Kropiwnicka A; Drzewoski J
Thromb Res; 2004; 113(2):101-13. PubMed ID: 15115665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
